

CytoSorbents Corporation

NASDAQ CM: CTSO

An Emerging Leader in
Critical Care Immunotherapy

Year 2014 Earnings Call
March 31, 2015



Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents, Inc (now known as CytoSorbents Medical Inc) and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies' products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company's Form 10-K filed with the Securities and Exchange Commission on March 31, 2015 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.

CytoSorbents is Well-Positioned as A Leader in Critical Care Immunotherapy



Leading the Prevention or Treatment of
Life-Threatening Inflammation in the ICU and
Cardiac Surgery using CytoSorb® Blood Purification



CytoSorbents

Working to Save Lives Through Blood Purification

2014: A Strong Year of Growth




CytoSorbents


Working to Save Lives Through Blood Purification

Achieved 2014 CytoSorb Sales of \$3.1M

Driven by a growing combination of Direct Sales, Independent Distributor Sales, and Strategic Partner Sales



2nd CytoSorb Germany User's Meeting



1st International CytoSorb User's Meeting



ISICEM 2015



More Published Case Reports & Studies

Romanian Journal of Anaesthesia and Intensive Care 2014 Vol 21 No 2, 134-138

Effects of a novel cytokine haemoadsorption system on inflammatory response in septic shock after cephalic pancreatectomy – a case report

Dana Tomescu^{1,4}, Simona O. Dima², Sabina Tănăsescu¹, Cristiana Pistol Tănase³, Anca Năstase², Mihai Popescu⁴

Int J Artif Organs 2014; 37 (00): 000-000
DOI: 10.5301/ijao.5000315

SHORT COMMUNICATION

Septic shock secondary to β -hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy

Hubert Hetz¹, Reinhard Berger¹, Peter Recknagel², Heinz Steltzer¹

¹AUVA Meidling Emergency Hospital, Department of Anesthesiology and Intensive Care Medicine, Vienna - Austria
²Integrated Research and Treatment Center, Center for Sepsis Control and Care, Jena University Hospital, Jena - Germany

LETTER FROM THE FRONTLINE

LIVER TRANSPLANTATION 20:1523-1524, 2014

First Description of Single-Pass Albumin Dialysis Combined With Cytokine Adsorption in Fulminant Liver Failure and Hemophagocytic Syndrome Resulting From Generalized Herpes Simplex Virus 1 Infection

Blood Purification

Letter to the Editor

Blood Purif 2013;35:314-315
DOI: 10.1159/000351206

Published online: July 31, 2013

Improvement of Hemodynamic and Inflammatory Parameters by Combined Hemoadsorption

Int J Artif Organs 2015; 00(00): 000-000
DOI: 10.5301/ijao.5000382

ISSN 0391-3988

SHORT COMMUNICATION

First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report

Case Report

Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study

Reshma Basu, Sunjay Pa...

ASAIO Journal 2015

Case Reports

Cytosorb™ in a Patient with Legionella-Pneumonia Associated Rhabdomyolysis: A Case Report

Marion Wiegele and Claus G. Krenn

Case reports

Early report: The use of Cytosorb™ haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations

Craig Morris¹, Lewis Gray² and Marco Giovannelli¹

Journal of the Intensive Care Society
0145 2149
© The Intensive Care Society 2015
Reprints and permissions:
sagepub.co.uk/
journals/permissions.nav
DOI: 10.1177/0145214915071507485
jics.sagepub.com
SAGE

F. Born, M. Pichlmaier, S. Peter, N. Ehsaladi, C. Hagl
Herzchirurgische Klinik und Poliklinik an der LMU München Campus Großhadern
Herzklinik am Augustinum
(Direktor: Prof. Dr. med. Christian Hagl)

Systemic Inflammatory Response Syndrome in Heart Surgery: New possibilities for treatment through the use of a cytokine adsorber during ECC?



Launched International CytoSorb Registry

- The home of 40+ planned investigator initiated studies with many already enrolling

The screenshot shows the website's registration form on the left and a banner image on the right. The banner features a photograph of a surgeon in an operating room, with a blue overlay containing the text 'THE INTERNATIONAL CYTOSORB-REGISTRY' and 'starts in November 2014'. The registration form includes fields for Title, Address, Name, Prenom, Hospital, department, Street No., Country, Email Address, and Phone. A 'SUBMIT' button is located at the bottom of the form. The website header includes contact information (+49 3641 9-396655, zks@med.uni-jena.de), a search bar, and navigation links (HOME, BACKGROUND, THE INTERNATIONAL CYTOSORB REGISTRY, JOIN THE REGISTRY, CONTACT, LOGIN).

CytoSorb Registry

REGISTRATION FORM

S.-Allende-Platz 27, 07747 Jena

Title

Address

Name, Prenom

Hospital, department

Street No.

Country

Email Address

Phone

SUBMIT +49 3641 9-396655
zks@med.uni-jena.de

THE INTERNATIONAL CYTOSORB-REGISTRY
starts in November 2014

Welcome to the International CytoSorb-Registry website!

Launched New CytoSorb Website

Contact: +49 30 654 99 145 info@cytosorb-therapy.com DE f Search ...

CytoSorb®

The Therapy The Studies The Adsorber Customer Service About us

SIRS and SEPSIS in Cardio-thoracic Surgery

Regain control

THE THERAPY
Facts and background information on mode of action

THE FIELDS OF APPLICATION
Discussion on current and potential applications

THE ADSORBER
Explanations of the mechanisms of action and the practical application

THE STUDIES
Current, published and planned studies on evidence creation

CytoSorb The international CytoSorb registry Universitätsklinikum



Partnered with Global Leaders



CytoSorbents

Working to Save Lives Through Blood Purification

Expansion of Biocon Partnership

- According to Biocon, hundreds of patients have benefited from CytoSorb® therapy and orders continue to increase
- Expanded agreement beyond sepsis to all critical care applications and cardiac surgery with a focus on the systemic inflammatory response syndrome (SIRS) in India and select emerging countries
- Negotiated a co-development agreement where Biocon has committed to conduct and publish results from multiple Investigator Initiated studies and patient case studies
- Biocon will continue to market CytoSorb® with their critical care antibiotics as the “most comprehensive treatment” of sepsis
- Biocon has also agreed to an increase in annual minimum sales targets which should result in significantly increased sales over the life of the agreement



Fresenius Medical Care

- Entered into a 6 country partnership with Fresenius, the largest dialysis company in the world for exclusive distribution of CytoSorb® in critical care in France, Sweden, Norway, Finland, Denmark and Poland
- Leveraging Fresenius' #1 or #2 position in critical care in these territories and elsewhere in the world
- CytoSorb® is a key part of Fresenius' growth strategy in critical care
- Strong sales force and distribution
- CytoSorb has been used on the Fresenius multiFiltrate thousands of times
- Potential for much broader synergy and expansion in the future



Cardiac Surgery Initial Partnership

- Entered into an initial partnership with a top-four global medical device company in cardiac surgery to use CytoSorb® intra-operatively during cardiac surgery in France
- Initial evaluation phase expected to be complete in Q2 2015
- Following a successful evaluation, the two parties plan to jointly determine how to potentially expand upon both the size and geographic footprint of its partnership
- France is the second largest medical device market and one of the highest volume cardiac surgery markets in the EU
- Medtronic, Sorin, Maquet and Terumo are top firms in the cardiac surgery space worldwide



CytoSorbents


Working to Save Lives Through Blood Purification

Focus on Generating Clinical Data




FDA Approval of IDE for REFRESH Study

- REFRESH (Reduction in FRee Hemoglobin) Trial is a 20-patient multi-center feasibility study evaluating the safety of CytoSorb use intra-operatively in a bypass circuit in a heart-lung machine during complex cardiac surgery as a means of reducing plasma-free hemoglobin and other inflammatory mediators that can cause post-operative complications
- Expected to be completed this year, beginning the clinical trial process to seek US FDA approval for CytoSorb



Infrastructure to Drive Clinical Data



Increased Investor Awareness



NASDAQ Capital Market Listed

CytoSorbents (CTSO) Up-listed to NASDAQ in December 2014

- Average daily trading volume: 200K shares (\$3M daily trading value) vs 30,000 prior to up-listing





#11 on Forbes Best Performing Stocks of 2014

CytoSorbents Achieved Strong Stock Performance in 2014 comparing favorably to peers

Ticker	Company	Total return in 2014 (%)	Market capitalization (\$MIL)	Quarterly sales (\$MIL)
AVNR	Avanir Pharmaceuticals, Inc. Class A	404.5	3,284.5	32.7
OVAS	OvaScience, Inc.	383.8	1,075.3	0.0
AGIO	Agios Pharmaceuticals, Inc.	367.8	4,103.9	33.9
BLUE	Bluebird Bio, Inc.	337.2	2,875.6	6.4
RCPT	Receptos, Inc.	322.6	3,792.8	3.5
TGTX	TG Therapeutics, Inc.	306.2	696.4	0.0
RNA	Prosensa Holding NV	301.5	677.0	0.0
PTX	Pernix Therapeutics Holdings PTX +2.23% , Inc.	272.6	359.6	31.5
ACHN	Achillion Pharmaceuticals ACHN -8.13% , Inc.	269.1	1,228.0	0.0
FOLD	Amicus Therapeutics, Inc.	254.0	774.7	0.3
CTSO	CytoSorbents Corporation	218.4	251.6	1.2
PTCT	PTC Therapeutics, Inc.	205.1	1,739.6	1.7
ESPR	Esperion Therapeutics, Inc.	194.3	823.0	0.0
TTPH	Tetraphase Pharmaceuticals, Inc.	193.7	1,217.4	2.3
ISR	IsoRay, Inc.	192.0	80.1	1.0
ANIP	ANI Pharmaceuticals Inc	180.8	638.9	17.4
CMRX	Chimerix, Inc.	166.4	1,468.5	1.2
CBMG	Cellular Biomedicine Group, Inc.	153.1	128.4	0.1
HRT	Arrhythmia Research Technology, Inc.	142.9	21.2	6.0
NBIX	Neurocrine Biosciences, Inc.	139.2	1,698.0	0.0

Continued Positive Analyst Coverage and Investor Outreach

COMPANY UPDATE (CTSO/ NASDAQ) **BREAN CAPITAL, LLC**

CytoSorbents Corporation
February 19, 2015

Jonathan Aschoff, (212) 702-6652
Yi Cheng, (212) 702-6620

jaschoff@breancapital.com
YCheng@breancapital.com

CytoSorb Appears To Us To Be Worth Using To Alleviate CRS After CAR T Therapy

Buy
TP: \$25.00

Price: \$9.09, \$4.40, 24.5, \$223, 1,206, NA, 1.0%, SE, 0

H.C.WAINWRIGHT & CO.

CytoSorbents Corp (CTSO)
Rating: Buy

Expanding Horizons; New \$12 Price Target; Reiterate Buy

Exciting year for CytoSorb development. At the end of 2014, CytoSorbents submitted an Investigational Device Exemption (IDE)

Target Price Revision Medical Device
January 27, 2015

Swayampakula Ramakanth, Ph.D.
212-356-0544
sramakanth@hcrwresearch.com

Stock Data 01/26/2015 Price \$8.14

EQUITY RESEARCH Healthcare | Medical Devices **MLV & CO**
March 5, 2015

Initiating Coverage

CytoSorbents Corp.
Staking A Claim In Sepsis And Cardiac Surgery

TICKER NASDAQ: CTSO BUY
RATING \$30.00
PRICE TARGET \$10.87
Price (March 04, 2015)

Market Data \$266.4
Market Cap (M): 24.5

We are initiating coverage of CytoSorbents Corp., an emerging blood purification company, with a BUY rating and a 12-month price target of \$30 per share. In our view, CytoSorbents is an unusual technology platform firm with a marketed

Buy

WBB Securities, LLC
Stephen G. Brozak • sbrozak@wbbsec.com • (908) 518-7610

INITIATING COVERAGE – FEBRUARY 25, 2015
CytoSorbents Corporation (NasdaqCM: CTSO)

Initiating Coverage with a Speculative Buy Rating and One-Year Price Target of \$13.00

12 Month Target Price \$13.00
12 Month Trading Range \$4.40-\$12.87
Market Capitalization (Mil) \$267.87
Shares Outstanding (Mil) 24.5

Merriman Capital **CytoSorbents Corporation (CTSO)**
CTSO Update Post Completion Of Quiet Period
January 19, 2015

Andrew D'Silva, Analyst (415) 568-3927 adsilva@merrimanco.com

Investment Conclusion
CytoSorbents (CTSO) has developed a potentially breakthrough technology to extract inflammatory mediators such as cytokines and toxins from blood in critically ill patients with a wide range of inflammatory conditions such as sepsis, trauma, lung injury, burn injury, pancreatitis and many others. The company's various technologies are centered around its highly porous polymer beads which are backed by 32 issued U.S. patents. The company has begun aggressive sales initiatives outside the U.S. and has begun around its highly porous polymer beads which are backed by 32 issued U.S. patents. The company has begun aggressive sales initiatives outside the U.S. and has begun around its highly porous polymer beads which are backed by 32 issued U.S. patents. The company has begun aggressive sales initiatives outside the U.S. and has begun around its highly porous polymer beads which are backed by 32 issued U.S. patents. **We are believe the company's current price adequately accounts for the value inherent in the process to obtain domestic regulatory approval as well. Furthermore, we do not believe the commercialization of CytoSorb®, its market potential or takeout value. We are maintaining our BUY rating on CTSO shares; however, to account for a recent 25:1 reverse split we are adjusting our PT to \$18.75 from \$0.75 previously.**

Price:	\$8.33
Price Target:	\$18.75
52-Week Range:	\$4.40-\$12.87
Cash (M):	\$7.8
Debt (M):	\$0.0
Net Cash/Share:	\$0.32
Book Value/Share:	\$(0.44)

Zacks Small-Cap Research
December 18, 2014
Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474
111 North Canal Street, Chicago, IL 60606

CytoSorbents Cp (CTSD-OTCBB)

CTSOD: Fresenius Adds More Than Just Marketing Muscle...

OUTLOOK
CytoSorb was CE Marked in March 2011 and subsequently commenced its initial commercialization. Initial focus on building awareness appears to be paying off. CTSD now generating clinical outcomes data which is just starting to be used to accelerate adoption and utilization. CTSD now expects to pursue cardiac surgery indication in the U.S. as this may provide the lowest cost, easiest and fastest route to the U.S. market. Cardiac surgery indication has driven substantial interest overseas with successful outcomes. Gov't contracts/grants that CTSD continues to score also aid their awareness-building efforts, cash flow as well as also aid their awareness-building efforts, and further increase visibility and credibility of the technology, and the potentially expand the menu of potential applications of the device. Interest in and use of CytoSorb from hospitals and physicians continues to increase. Also seeing great interest from

Current Recommendation	Outperform
Prior Recommendation	N/A
Date of Last Change	06/04/2012
Current Price (12/17/14)	\$6.60
Target Price	\$12.50

Increased Media Coverage

+ MASS DEVICE

CytoSorbents inks deal with Fresenius Medical Care ([link](#))
 By Mark Hollmer
 Mass Device
 December 16, 2014

Fresenius Medical Care is slated to distribute CytoSorbents' cytokine blood purification filters in several countries as part of a new strategic partnership.

CytoSorbents (OTC:CTSO) said yesterday that it scored an international strategic partnership with Fresenius (NYSE:FMS) that will boost access to international markets for its cytokine blood purification

MEDICAL DEVICE DAILY™

THE DAILY MEDICAL TECHNOLOGY NEWS SOURCE

People in the News
 Medical Device Daily
 December 24, 2014

CytoSorbents (Monmouth Junction, New Jersey), a critical care focused immunotherapy company marketing its CytoSorb blood purification technology to help fight deadly inflammation in critically-ill and cardiac surgery patients, reported the appointment of Gregory Di Russo, as its Senior Vice President of Clinical Development, effective Jan. 5, 2015. Di Russo is an accomplished pediatric cardiothoracic surgeon specializing in congenital cardiac surgery and was Vice Chairman of Cardiothoracic Surgery at

Cardiovascular News

CytoSorbents submits IDE application for US CytoSorb cardiac surgery trial ([link](#))
 By Dawn Powell
 Cardiovascular News
 January 2, 2014

CytoSorbents has submitted an Investigational Device Exemption (IDE) application to the US Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.

FDANEWS

Simplifying Global Compliance

CytoSorbents Files IDE for CytoSorb Cardiac Surgery Trial ([link](#))
 By Kellen Owings
 FDANews
 January 2, 2015

FierceDrugDelivery

Cytosorbents no longer an OTC stock, uplists to Nasdaq ([link](#))
 By Varun Saxena
 FierceDrugDelivery
 December 24, 2014

Starting today, CytoSorbents, maker of the CytoSorb extracorporeal cytokine adsorber to reduce

MICROCAP DAILY

Cytosorbents Corp (NASDAQ:CTSO) Rebounding on a Stronger Note ([link](#))
 By James Elliot
 MicroCap Daily
 December 30, 2014

Cytosorbents Corp (NASDAQ:CTSO) is coming back strong after a shack to just over \$9 a share. The stock has been upwards on huge strength in recent days hitting a high of \$12.86. The ticker symbol changed back to CTSO from CTSD after the 1 for 25 reverse split of the stock. The Company announced on December 15 that its common stock has been approved for listing on The NASDAQ Capital Market. Shares are expected to begin trading on The NASDAQ Capital Market on Tuesday, December 23, 2014 under the ticker symbol "CTSO".

BioCentury

CytoSorbents Corp. (OTCQB:CTSD), Monmouth Junction, N.J.
 By Staff Writer
 BioCentury
 December 15, 2014

FierceMedicalDevices

Fresenius adds blood purification tech to its dialysis offerings via partnership ([link](#))
 By Varun Saxena
 FierceMedicalDevice
 December 16, 2014

Dialysis magnate Fresenius Medical Care, a leading provider of hemodialysis machines, has entered into a partnership to help commercialize the cytokine adsorber CytoSorb to combat sepsis and other infections that can lead to organ failure. The financial terms of the pact with product developer CytoSorbents were not disclosed.

The blood purification therapy CytoSorb complements Fresenius' extensive



Operating and Financial Highlights



CytoSorbents


Working to Save Lives Through Blood Purification

2014 Comparative Revenue Results


	2014	2013	% Incr.
Product revenue	\$ 3,135,387	\$ 821,787	282%
Grant and other income	987,438	1,600,880	(38)%
Total revenue	\$ 4,122,825	\$ 2,422,667	70%

- Achieved record CytoSorb® annual sales of \$3.1 M, a 282% increase over \$822K in 2013.
- Grant and other income declined by 38% as a result of the conclusion of several significant grants.
- Gross margin on product sales in 2014 were approximately 63%, as compared to 61% for 2013.

Rapidly-Growing Year-Over-Year Product Sales




Quarterly Product Sales



- Q4 2014 Product Revenue were \$871K, an increase of \$557K or 177% over Q4 2013 product revenues of \$314K.
- Q4 2014 product revenues were approximately \$161K lower than Q3 2014 revenues. Q3 2014 was the first quarter where distributor sales exceeded direct sales, and due to the bulk nature of distributor orders, sales can fluctuate from quarter to quarter.



Product Sales Trends Remain Strong



Balance Sheet and Cap Table

Consolidated Balance Sheet Data:

12/31/2014

Cash and Short-Term Investments	\$	5,549,827 *
Total Assets	\$	8,468,625
Total Debt	\$	-
Total Shareholder's Equity	\$	3,963,183 *

* Does not reflect an additional \$10.3M financing completed in January 2015.

CytoSorbents Cap Table (Pro-Forma as of 3/31/2015)

Common stock outstanding	24,637,822 **
Options	2,192,171
Warrants	1,517,346
Fully-diluted Common shares	<u>28,347,339</u>

**Includes 1,250,000 shares issued in connection with the January 2015 \$10.3 financing.



Outlook for 2015



\$20 Billion Opportunity in Critical Care

Millions of people are admitted to the intensive care unit in hospitals in the U.S. and the European Union each year with deadly inflammatory conditions

Sepsis

ARDS



Burn Injury

Trauma

Pancreatitis

Influenza

Surgical



- In these conditions, massive inflammation driven by a “cytokine storm” causes cell death and organ failure. Nearly half of all deaths in the ICU is due to organ failure with no effective therapies
- Because of the lack of effective therapies, approximately 1 in every 3 patients dies
- The costs can be staggering: Lack of “active” therapies lead to patients lingering days to weeks in the ICU at \$2,000-3,000 per day in the ICU* on average
- Not surprising that we spend nearly 1% of our GDP on critical care**

* Cooper, L, et al, Crit Care Med 2004, 32(11):2247-2253.

** Halpern, NA, et al., Crit Care Med 2010, 38(1):65-71.




CytoSorb® Removes the Fuel to the Fire


- CytoSorb® represents a powerful immunotherapy to control inflammation
- Approved in the European Union as the only specifically approved cytokine filter
- Clinically proven to remove key cytokines in the blood of critically-ill patients
- Approved for use in any situation where cytokines are elevated
- Safe: ~5,500 human treatments, safe and well-tolerated



Goal: To Prevent or Treat Organ Failure




Improve
Patient
Outcome
and
Survival




Decrease
Costs Of
ICU and
Patient
Care

Sepsis



ARDS



Burn Injury



Trauma



Pancreatitis



Influenza



Surgical



The Potential to Revolutionize Critical Care Medicine



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorbents Has Tremendous Potential

CytoSorb® may help revolutionize critical care medicine,
saving lives, and reducing costs

- Massive untapped \$20 billion unmet, medical need in critical care
- CytoSorb® sales are generating significant growth with attractive 65% gross margins
- Continued geographic expansion throughout the world
- FDA approval to start U.S. cardiac surgery pilot study – the first phase to seek U.S. approval with CytoSorb®
- Expansion of existing strategic partnerships and potential new ones
- NASDAQ Capital Market up-listing and clean cap structure dramatically changes profile of company and ability for institutional and retail investors to invest

Near Term Challenges

Sales Infrastructure Targets For 2014

2013		
Direct Sales	Distributors	Partners
Germany Austria Switzerland	5 Distributors (UK, Ireland, Netherlands, Turkey, Russia)	Biocon (India)
4 sales reps		
Clinical Support (1)		
US Manufacturing + QA/QC Staff		
Reimbursement		

Targets for 2014		
Direct Sales	Distributors	Partners
Germany Austria Switzerland	10+ Distributors	2+ Partners
10 sales reps	Distributor/Partner Support Rep	
Clinical Support Staff (2)		
Support increases in sales with increases in US Manufacturing + QA/QC Staff		
Reimbursement Support		



Restructuring Targets For 2015

Q1 2015		
Direct Sales	Distributors	Partners
Germany ----- Austria Switzerland	8 Distributors	Biocon Fresenius Global Cardiac Surgery Co.
4 sales reps	International Sales Director + Export Business Manager	
Clinical and Product Support (2) Medical Director, Head of Scientific Marketing (2)		
US Manufacturing + QA/QC Staff		
Reimbursement Support		

Targets for 2015		
Direct Sales	Distributors	Partners
Germany ----- Austria Switzerland	12 or more Distributors total	5 or more Partners total
10 sales reps	International Sales Director + Export Business Manager	
Clinical and Product Support (2) Medical Director, Head of Scientific Marketing (2)		
US Manufacturing + QA/QC Staff		
Reimbursement Support		

Q1 2015 Revenue Guidance


- In general, our product sales are too dependent on the timing and size of orders and cannot yet be accurately predicted
- We have given guidance, however, when data from the full quarter is known
- Expect that Q1 2015 CytoSorb product revenue will be in the range of \$700,000 - \$ 725,000 (unaudited). Adjusting for the impact in the change of the Euro, which has dropped 22% from a year ago, this is equivalent to an adjusted range of \$800,000 - \$850,000

Q&A Session

CytoSorbents Corporation

NASDAQ CM: CTSO

Phillip P. Chan, MD, PhD - CEO
7 Deer Park Drive, Suite K
Monmouth Junction, NJ 08852
pchan@cytosorbents.com



An Emerging Leader in Critical Care Immunotherapy



CytoSorbents

Working to Save Lives Through Blood Purification